About Stella Diagnostics
Stella Diagnostics is a company based in New York (United States) founded in 2020 was acquired by Jmdproperties in September 2020. Stella Diagnostics operates in a competitive market with competitors including Prometheus Laboratories, Viome Life Sciences, InDex Pharmaceuticals, NinePoint Medical and Given Imaging, among others.
- Headquarter New York, United States
- SectorsHealthcare
- Email••••••••
- Website stelladx.com
- Acquired by Jmdproperties (Sep 2020)
- Legal Name Stella Diagnostics Inc.
- Annual Revenue$1.78 M (USD)0as on Dec 31, 2025
- Net Profit-$4.06 M (USD)-228.38as on Dec 31, 2025
- EBITDA-$3.45 M (USD)-239.78as on Dec 31, 2025
- InvestorsKeystone Capital Partners
& 1 more
- Acquired byJmdproperties
(Sep 2020)
Funding Insights of Stella Diagnostics
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Stella Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | – | Seed | – | Keystone Capital Partners | – |
2 investors in total: 2 institutional.
Investors in Stella Diagnostics
Stella Diagnostics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Keystone Capital Partners and Jmdproperties.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
An investment firm based in New York is operated. | – | keystone-cp.com | New York, United States | |
- | – | jmdproperties.com | - |
Investor details for Stella Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Stella Diagnostics
1 people are tracked at Stella Diagnostics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Joe Abdo | CEO | Leadership |
Complete people profiles for Stella Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Stella Diagnostics
Stella Diagnostics is a publicly listed company on the OTC with ticker symbol SLDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onOTC: SLDX
- Listed entitySTELLA DIAGNOSTICS INC.
- Exchange sectorHealth technology
- ISINUS85853Y1047
- Share price$0.01 (+24.1% on the day) · 2026-10-01
- Market capitalisation$3.0M
- EPS (diluted, trailing year)$-0.01
- Volume (last session)1,000
Financials of Stella Diagnostics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.8M | -$4.1M | -$3.5M |
| 2024 | – | -$1.2M | -$1.0M |
| 2023 | – | -$5.7M | -$11.4M |
| 2022 | – | -$5.6M | -$2.5M |
| 2021 | – | -$16.6M | -$4.7M |
Detailed financial statements for Stella Diagnostics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Stella Diagnostics
3 dated milestones of Stella Diagnostics, from founding to its latest funding, stage changes and deals.
- Founded Stella Diagnostics is founded.
- Funding First funding round.
- Exit Acquired by Jmdproperties.
Competitors of Stella Diagnostics
Stella Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prometheus Laboratories, Viome Life Sciences, InDex Pharmaceuticals, NinePoint Medical and Given Imaging, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| prometheuslabs.com | 1995 | San Diego, United States | – | 474 | Diagnostics and therapeutics for gastrointestinal and personalized medicine are developed. | |
| viomelifesciences.com | 2016 | Bothell, United States | $92.44M | 136 | Provider of tests to prevent, treat, and cure chronic diseases, and cancer | |
| indexpharma.com | 2000 | Stockholm, Sweden | $45.42M | – | DNA-based immunomodulatory drugs for ulcerative colitis are developed. | |
| ninepointmedical.com | 2008 | Bedford, United States | $98.26M | 25 | Optical coherence tomography systems for tissue microstructure imaging are developed. | |
| givenimaging.com | 1998 | Minneapolis, United States | – | – | Capsule endoscopy systems for GI imaging | |
| enterasense.com | 2016 | Galway, Ireland | $1.14M | – | Ingestible biosensor for GI disease | |
| gtechmedical.com | 2010 | Mountain View, United States | $6.93M | 3 | Diagnostic device company | |
| venterpharma.com | 2003 | Alcobendas, Spain | – | – | Diagnostic drugs for lactose intolerance are developed. | |
| lifetag.pt | 2016 | Cantanhede, Portugal | – | – | Developer of diagnostic kit for intestinal permeability | |
| optimede.com | 2011 | Seoul, South Korea | – | – | Developer of disposable and portable endoscopes |
Detailed competitors of Stella Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stella Diagnostics
Complete news archive for Stella Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Stella Diagnostics
10 companies that operate in the same segment as Stella Diagnostics (Gastroenterology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Implantable battery-powered pumps for ascites removal are developed. | 2006 | Zurich, Switzerland | USD 35.5 M | – | – | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | – | 533 | |
Developer of electrosurgical system and range of flexible endoscopic instruments | 2003 | Chepstow, Monmouthshire, United Kingdom | USD 20.84 M | USD 8.08 M | 141 | |
Non-invasive biomarker tests for colorectal cancer are developed. | 2015 | St. Louis, Missouri, United States | USD 218.95 M | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | 2009 | Ramat Gan, Tel Aviv District, Israel | USD 13.5 M | USD 288.27 K | 35 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Stella Diagnostics
Stella Diagnostics was founded in 2020.
Stella Diagnostics is headquartered in New York, United States. It is registered at New York, New York, United States.
Joe Abdo is the current CEO of Stella Diagnostics.
Annual revenue of Stella Diagnostics is $1.78M as on Dec 31, 2025.
Stella Diagnostics was founded in 2020 and is based in New York, United States. Operations focus on the biotechnology sector, where molecular diagnostics solutions for severe esophageal diseases are created. Novel biomarkers have been developed to target proteomic changes associated with disease progression, including cellular proliferation and survival. Mass spectrometry proteomics assays are also provided to support diagnostic needs.
Stella Diagnostics's top competitors include Viome Life Sciences, Prometheus Laboratories and NinePoint Medical.
Yes, Stella Diagnostics is publicly traded on OTC under the ticker symbol SLDX.
Stella Diagnostics has 2 investors. Key investors include Keystone Capital Partners, and Jmdproperties.
Yes. Stella Diagnostics was acquired by Jmdproperties in September 2020.